Diagnostic methods are limited for detecting microscopic soft tissue metastases in patients with prostate cancer. Previous studies using 111 Indium Capromab Pendetide (ProstaScint TM scan) analyzed patients with extensive localized tumor (prostate specific antigen (PSA) > 20 ng/ml) not optimal for surgical therapy. We evaluated the role of the ProstaScint TM scan in a preoperative population to provide histological documentation and to assess its utility in a surgical population. A total of 22 preoperative patients, underwent a ProstaScint TM scan. The mean preoperative PSA was 16.0 ng/ml (range 3.9 -33 ng/ml). The mean Gleason score at biopsy was 6.9 (range 6 -9). Each patient underwent a radical retropubic prostatectomy and bilateral pelvic lymph node dissection, which included resection of both obturator and common iliac lymph nodes. Histologic analysis of the resected lymph nodes provided the standard of comparison with the ProstaScint TM scan. The results of the scan and pathology for all 22 patients were compared with the bilateral obturator and iliac nodes, creating 88 data points. Nine areas (10%) were positive on the scan. One of these (11%) was a true positive while the other eight (89%) were false positives. Seventy-nine areas (90%) were negative on scan results. Of these, five areas (6%) were false negatives and 74 areas (94%) were true negatives. The scan yielded a sensitivity of 17%, specificity of 90%, negative predictive value (NPV) of 94% and a positive predictive value (PPV) of 11%. The high false positive rate and low PPV of ProstaScint scans overestimates metastatic lymph nodes disease, and is not useful when used preoperatively.
Introduction
Efforts to improve clinical staging and identification of occult metastatic prostate cancer are instrumental in properly treating patients with prostate cancer. Currently, choosing the appropriate treatment is difficult because of the lack of diagnostic modalities that can accurately identify local or regional metastases and recurrences. Computerized tomography (CT) and magnetic resonance imaging (MRI) have been ineffective in identifying lymph node metastases due to their low sensitivity and high false negative rates. Although serum prostate specific antigen (PSA) has been a very sensitive test for detecting treatment failures, it does not indicate the specific site(s) of failure. Therefore, the most accurate way of assessing regional metastatic disease is by performing bilateral pelvic lymphadenectomy.
The 111 Indium labeled murine monoclonal antibody scan (ProstaScint TM scan), which is directed against prostate specific membrane antigen (PSMA), is being increasingly recognized as a potential diagnostic aid because it is a noninvasive modality to assess lymphatic spread. Previous studies reviewing the use of the ProstaScint TM scan report higher sensitivities compared with CT and MRI and conclude that it is a reliable diagnostic aid. This study evaluated the outcome of ProstaScint TM scintigraphy by comparing the scan results of preoperative patients to the pathology of lymph nodes by site-specific analysis after each patient had undergone pelvic lymphadenectomy and radical prostatectomy. The objective of the study was to determine if the ProstaScint TM scan is useful in the detection of lymph node metastases in a pre-surgical patient.
Materials and methods
From January 1998 through November 1999, 22 patients with histologically confirmed, untreated adenocarcinoma of the prostate, with a negative bone scan and negative CT evaluation of the abdomen and pelvis were eligible for enrolment in this study, and referred for ProstaScint TM imaging. The mean preoperative PSA level was 16.0 ng/ ml (range 3.9 -33 ng/ml) and the mean Gleason score was 6.9 (range 6 -9).
Nineteen of the 22 patients in this study were scanned in the Department of Nuclear Medicine at the Cleveland Clinic Foundation. The other three scans were performed at outside, unaffiliated institutions. All of the scans were reviewed by one nuclear medicine specialist (DN). Following the i.v. administration of 111 Indium ProstaScint, immediate SPECT images were obtained for vascular anatomy correlation. Between 48 and 120 h after the injection, whole body imaging and SPECT of the chest, abdomen, and pelvis were performed. Within 180 days of the 111 In-Capromab Pendetide infusion, all patients underwent radical retropubic prostatectomy and an extensive bilateral pelvic lymph node dissection by a single surgeon (CDZ). The aortic bifurcation was the cephalic limitation of the dissection without exposing the intraperitoneal structures. Positive scan areas in the small bowel mesentery and surrounding the distal and mid aorta were not explored.
Pathological analysis of the surgically resected pelvic lymph nodes provided the standard with which the radiolabeled monoclonal antibody scan was compared. The obturator lymph nodes and the iliac lymph nodes were histologically examined for each patient and were correlated to the scan. Specificity, sensitivity, positive predictive value, and negative predictive value were calculated.
Results
Twenty-two preoperative prostate cancer patients were studied. The mean preoperative PSA in our series was 16.0 ng/ml, the mean Gleason score was 6.9, and the clinical stages were as follows: T 1 C (32%); T 2 (45%); and T 3 (23%). The results of the scan and pathology were compared in four areas: right and left obturator nodes and right and left iliac nodes. Analysis of these four areas for each patient gave a total of 88 data points.
Overall, nine areas in seven different patients had positive ProstaScint TM images for pelvic lymph node metastases. Of these nine areas, one (11%) was a true positive and eight areas (89%) were false positives. The true positive result was found in the iliac region as well as seven of the eight false positives. The other false positive was an obturator node.
Seventy-nine areas (90%) had negative ProstaScint TM images. Of these, five areas (6%) were false negatives and 74 areas (94%) were true negatives. Specifically, 40 obturator nodes and 34 iliac nodes accounted for the true negatives. Out of the five false negatives, three were obturator nodes and two were iliac nodes.
These results yielded a sensitivity of 17%, a specificity of 90%, a positive predictive value of 11%, and a negative predictive value of 94%. When the results were broken down by site, the sensitivity was 0% for the obturator nodes and 33% for the iliac nodes. The specificity was 98% for the obturator nodes and 83% for the iliac nodes.
Of the 22 patients, all of them had histological evidence of adenocarcinoma in the prostate specimen. Interestingly, the ProstaScint TM scan was positive in the prostatic fossa in only 10 out of the 22 patients for a sensitivity of 45%.
Discussion
Accurate clinical staging of prostate cancer is limited due to our inability to detect microscopic extracapsular or nodal disease. Neither of our current modalities for staging soft tissue metastases such as CT or MRI are specific or sensitive enough to detect microscopic disease. Recently, there has been considerable enthusiasm for 111 Indium Capromab Pendetide (ProstaScint TM scan) in the detection of microscopic prostate cancer. 1, 2 The ProstaScint TM scan has generally been used to stage and detect local recurrences following treatment failures from either radiation therapy or radical prostatectomy. Elgamal et al, 3 reported a sensitivity of 89% for the detection of lymph node metastases in patients who had failed radical prostatectomy or radiation therapy. In this study the mean PSA was exceptionally high at 55.9 ng/ml. Histological confirmation was obtained using percutaneous lymph node biopsy specimens. The ability to do a percutaneous lymph node biopsy would indicate that there was observable lesions seen on CT scan, reflecting the high mean PSA. This patient population is in contrast to most surgical series where pelvic adenopathy is not seen on preoperative CT scanning. When the ProstaScint TM scan was used to detect recurrent prostate cancer at a lower serum PSA, the sensitivity decreased considerably. Kahn et al, 4 in a series of 181 patients with biochemical failure following radical prostatectomy, reported a sensitivity and positive predictive value of 49 and 50%, respectively. In this series, the mean serum PSA at the time of local recurrence was 7.9 ng/ml with a range of 0.2 -82.5 ng/ml.
Another role of the ProstaScint TM scan is to detect potential regional and distant metastases in newly diagnosed patients. Hinkle et al 5 evaluated the ProstaScint TM scan in 51 newly diagnosed patients having an exceptionally high mean PSA of 53.2 ng/ml (range 1.0 -350.9 ng/ ml) prior to definitive treatment. In comparing the scan results with pelvic lymph node dissections, Hinkle et al 5 reported a high sensitivity and positive predictive value of 75 and 79%, respectively. Similar to Elgamal's study, this high sensitivity in Hinkle's series reflects the large 6 in a pre-surgical series of 198 patients, showed a sensitivity of 61.5%, specificity of 80%, positive predictive value of 66.7%, and negative predictive value of 76.2%. The average serum PSA in this series was also high, at 57.2 ng/ml (range 1.0 -563 ng/ml).
Our results showed a significantly lower sensitivity at 17% and demonstrated that the positive predictive value was sub-optimal in both the obturator (0%) and iliac (33%) nodes. We specifically analyzed these two nodal areas because the lymph nodes could be easily removed through the standard midline infraumbilical incision without committing to a retroperitoneal or intraperitoneal procedure. We did not open the posterior peritoneum to examine other areas within the small bowel mesentery that are sometimes read as positive on the scan. As described by Kahn et al, 4 these false positive areas in the small bowel mesentary can result from accumulation of the antibody in areas of inflammation or activity in the mesentary vessels. In our study, we postulate that the sensitivity and PPV are lower due to the differences in tumor volume in our study population, as reflected by our lower mean PSA (16.0 ng/ml). Polascik et al studied a patient population with biopsy proven clinical T 2 or T 3 prostate cancer with multiple other high risk features. In Polascik's study, the patients were considered to be at significant risk of lymph node metastases based on the following criteria: (1) PSA 10 times the upper limit of normal with Gleason score 7; (2) PSA 8 times the upper limit of normal with equivocal evidence of extraprostatic disease on CT or ultrasound; (3) Gleason score 8; (4) Gleason score 6 with clinical classification T 3 disease; or (5) Prostatic acid phosphatase above the upper limit of normal. As noted previously, the serum PSA values in his study prior to treatment ranged from 1.0 ng/ml to 563 ng/ml with a mean of 57.2 ng/ml, and 64% of the patients had clinical T 3 disease. This surgical series reflects patients at high risk for lymph node metastases and are not our routine candidates for radical prostatectomy.
Similar to the Polascik et al study, Manyak et al 7 in a pre-surgical series, using the identical criteria for highrisk patients as Polascik, reported a sensitivity of 62%, specificity of 72%, PPV of 62% and NPV of 72%. However, these patients would also be considered at high risk for lymph node metastases and would not be deemed suitable for surgical therapy by our standards.
There has been one reported surgical series approximating our series of patients. In 1994, Babaian et al 8 analyzed 19 surgical patients with a mean PSA of 22.8 ng/ml, a mean Gleason score of 7.3 and 17 of the 19 patients having clinical T 2 or T 3 cancers. They reported a sensitivity of 44%, specificity of 86%, PPV of 50% and NPV of 83% when they compared the results of the ProstaScint TM scan specifically with right and left pelvic lymph nodes. This sensitivity and PPV are again slightly higher than we report, but again, in this series the patients were at a higher risk for lymph node metastases.
Our impression on the utility of the ProstaScint TM scan differs considerably from a recent review by Lamb and Faulds, 9 which concluded that the ProstaScint TM scan was a valuable tool in staging patients. In this review, the authors felt that newly diagnosed patients with positive scan results could avoid surgery because a curative procedure was unlikely. They also concluded that for patients with suspected recurrent or residual disease after radical prostatectomy, a positive scan would negate the role for salvage radiotherapy.
However, our study would suggest that the low PPV or the high number of false positive results would inappropriately deny newly diagnosed patients definitive treatment from radical prostatectomy or radiation therapy. In patients with biochemical failure, the high number of false positive results would also deny salvage radiation therapy to a large subset of patients and compromise a potential secondary curative outcome. However, with patients who have failed radical prostatectomy, the benefit of the ProstaScint TM scan could be its high negative predictive value. Our high NPV of 94% is a consistent finding in other series. 6 -8 The relatively high specificity and negative predictive value may allow us to comfortably administer adjuvant radiation therapy in our surgical failures. A negative scan may also give us greater confidence in advising salvage prostatectomy in eligible patients who have failed radiation therapy.
The small number of patients included in this study is certainly a limitation. Also, we were interested specifically in the preoperative patient population, we did not evaluate any post-surgical or post-radiation patients. Therefore, we are unable to specifically evaluate and draw conclusion on the use of the ProstaScint TM scan in this patient population. An additional limitation of this study is that we did not open the posterior peritoneum to examine other areas within the small bowel mesentery that are sometimes read as positive on the scan. The results of this study may not necessarily be applicable to patients with poor risk preoperative parameters, such as higher serum PSA or higher Gleason score.
Conclusions
The data presented in this study supports our clinical observation that there is little value in obtaining a preoperative ProstaScint TM scan for the prediction of microscopic nodal disease. Therapeutic decisions regarding staging and treatment of newly diagnosed prostate cancer patients should not be based on the results of a ProstaScint TM scan due to its high false positive rates.
